Study of Single Dose Non-immunogenic Recombinant Staphylokinase Compared to Placebo for Treating Intermediate High-risk Pulmonary Embolism in Adults
Led by Supergene, LLC · Updated on 2025-12-05
486
Participants Needed
24
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a single bolus dose of non-immunogenic recombinant staphylokinase compared to a placebo in adults with intermediate high-risk pulmonary embolism PE who have stable blood pressure. This phase 3 trial addresses the need for safer thrombolytic treatments in patients who are at risk but do not have shock or low blood pressure, as previous thrombolytics had risks like hemorrhagic stroke. The study aims to improve outcomes while minimizing adverse effects in this patient group.
Participants receive either a quick intravenous injection of non-immunogenic recombinant staphylokinase or a matching placebo. The staphylokinase dose is 15 mg given as a single bolus over 10-15 seconds regardless of body weight. The placebo group receives a similar injection with saline solution. This treatment period is followed by monitoring to compare the effects and safety between the two groups.
During the study, participants will be assessed for clinical outcomes including death, hemodynamic collapse, and recurrent pulmonary embolism within 30 days. Additional measures include heart function and lung pressure evaluations within 24 hours and 30 days, along with monitoring for bleeding events and other adverse effects. The trial lasts for 30 days after treatment with ongoing safety checks, and participant consent and adherence to contraceptive use are required throughout the study period.
CONDITIONS
Brief Title
Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism
Research Team
S
Sergey S. Markin, MD, PhD
S
Sergey N. Tereschenko, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Verified diagnosis of intermediate high-risk pulmonary embolism within two weeks of symptom onset
Right ventricular dysfunction with RV/LV diameter ratio over 1.0 by imaging
Increased risk of early death or hemodynamic collapse based on blood pressure, respiratory rate, oxygen saturation, or heart failure
Elevated serum troponin I levels according to age criteria
Use of reliable contraceptive methods during the study and for three weeks after (for women and men where applicable)
Signed informed consent to participate in the study
You will not qualify if you...
High-risk pulmonary embolism with unstable blood pressure
Increased bleeding risk including recent extensive bleeding, hemorrhagic stroke, central nervous system diseases, recent surgeries or trauma
Severe liver disease or active hepatitis
Recent confirmed gastric or duodenal ulcer
Cancer with increased bleeding risk
Use of Dabigatran without prior idarucizumab
Arterial aneurysms or developmental artery/vein defects
Acute pancreatitis
Bacterial endocarditis or pericarditis
Suspected aortic dissecting aneurysm
Other conditions posing high bleeding risk per investigator
Pregnancy or breastfeeding
Known allergy to non-immunogenic recombinant staphylokinase
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Single day
Participants receive a single intravenous bolus of non-immunogenic recombinant staphylokinase or placebo to treat intermediate high-risk pulmonary embolism.
1 treatment visit (in-person)
Follow-up
Duration - Up to 30 days
Participants are monitored for safety and efficacy outcomes including death, hemodynamic collapse, recurrent pulmonary embolism, and adverse events.
Multiple visits within 30 days
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of Home-Based Exercise Effects on Mobility After Pulmonary Embolism
Acutelines Biobank to Improve Early Detection and Personalized Treatment of Acute Diseases
Tracking Patient Outcomes from Emergency Admissions
Long-Term Evaluation of Aspiration Thrombectomy Using Symphony and Prodigy Systems for Arterial, Venous, and Pulmonary Blood Clots
Studying the Link Between Anti-factor Xa Activity and Blood Clots in Critically Ill ICU Patients
Study of Artificial Intelligence in Multimodal Imaging to Improve Diagnosis and Management of Pulmonary Embolism in Patients Aged 14 and Older in China
Improving Prevention of Blood Clots in Hospitalized Patients Using a System-Wide Quality Program in China
Clinical Outcomes and Treatments for Pulmonary Embolism
A Study by the Bern Acute Pulmonary Embolism Registry
Comparing Clinical Surveillance and Anticoagulation Treatment
for Low-risk Patients with Isolated Subsegmental Pulmonary Embolism
Evaluating Portable Dynamic Chest X-Ray DDR for Lung Function Diagnosis in ICU Patients
A Study on Feasibility and Improved Diagnostic Accuracy Compared to Standard Imaging
Early Detection of Deep Vein Thrombosis in Critically Ill ICU Patients Using Twice Weekly Ultrasound Compared to Standard Care
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE.
Alexander I Kirienko, Stanislav G Leontyev, Sergey N Tereschenko...